Last reviewed · How we verify

NCT06965452

Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy

Recruiting now NA Last updated 19 August 2025
What this trial tests

NA trial testing Spinal angiography and embolization/ Embozene Microspheres in Facet Joint Arthropathy in 40 participants. Currently enrolling.

Timeline
12 August 2025
Primary endpoint
1 August 2026
1 August 2026

Quick facts

Lead sponsorNorthwell Health
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment40
Start date12 August 2025
Primary completion1 August 2026
Estimated completion1 August 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Northwell Health — full company profile →

Who can join

Adults 18 to 85, any sex, with Facet Joint Arthropathy or Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This single-site, single-arm study evaluates the feasibility, safety, tolerability, and efficacy of trans-arterial embolization (TAE) using Embozene microparticles for treating facetogenic pain due to facet arthropathy (osteoarthritis of the facet joints) in the lumbar spine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Facet Joint Arthropathy

Currently open trials in the same condition.

Other Northwell Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06965452.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing